InDevR develops and manufactures microarray technologies as well as novel solutions to support the life science industry.
InDevR has raised $9.0M in total funding. The most recent round was Series B. The last funding was announced in January 2023.
InDevR's investors include Adjuvant Capital, National Institute of Allergy and Infectious Diseases, bioMerieux, Colorado Office of Economic Development and International Trade.
InDevR is headquartered in Boulder, United States.
InDevR develops and manufactures microarray technologies as well as novel solutions to support the life science industry.
InDevR is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"InDevR — Funding & Investors." VCBacked, January 17, 2023, https://www.vcbacked.co/company/indevr. Accessed July 20, 2026.
VCBacked. (2023). InDevR — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/indevr
{{cite web |title=InDevR — Funding & Investors |url=https://www.vcbacked.co/company/indevr |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated